122 related articles for article (PubMed ID: 16673594)
21. Mesonephric remnant hyperplasia involving prostate and periprostatic tissue: findings at radical prostatectomy.
Chen YB; Fine SW; Epstein JI
Am J Surg Pathol; 2011 Jul; 35(7):1054-61. PubMed ID: 21606823
[TBL] [Abstract][Full Text] [Related]
22. Mucin-producing urothelial-type adenocarcinoma of prostate: report of two cases of a rare and diagnostically challenging entity.
Curtis MW; Evans AJ; Srigley JR
Mod Pathol; 2005 Apr; 18(4):585-90. PubMed ID: 15778694
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen.
Chan TY; Mikolajczyk SD; Lecksell K; Shue MJ; Rittenhouse HG; Partin AW; Epstein JI
Urology; 2003 Jul; 62(1):177-81. PubMed ID: 12837462
[TBL] [Abstract][Full Text] [Related]
24. [Prostate cancer histoseminar: Update of the 2016 WHO classification - case No. 8: Acinar prostatic adenocarcinoma, Gleason score 6 (3+3)].
Ferlicot S
Ann Pathol; 2017 Jun; 37(3):259-263. PubMed ID: 28522121
[No Abstract] [Full Text] [Related]
25. Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.
Sung MT; Jiang Z; Montironi R; MacLennan GT; Mazzucchelli R; Cheng L
Hum Pathol; 2007 Feb; 38(2):332-41. PubMed ID: 17134736
[TBL] [Abstract][Full Text] [Related]
26. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis.
Parsons JK; Gage WR; Nelson WG; De Marzo AM
Urology; 2001 Oct; 58(4):619-24. PubMed ID: 11597556
[TBL] [Abstract][Full Text] [Related]
27. Visually Estimated MRI Targeted Prostate Biopsy Could Improve the Detection of Significant Prostate Cancer in Patients with a PSA Level <10 ng/mL.
Lee DH; Nam JK; Park SW; Lee SS; Han JY; Lee SD; Lee JW; Chung MK
Yonsei Med J; 2016 May; 57(3):565-71. PubMed ID: 26996553
[TBL] [Abstract][Full Text] [Related]
28. Clinical utility of percent prostate needle biopsy tissue with cancer cutpoints to risk stratify patients before radical prostatectomy.
Freedland SJ; Csathy GS; Dorey F; Aronson WJ
Urology; 2002 Jul; 60(1):84-8. PubMed ID: 12100929
[TBL] [Abstract][Full Text] [Related]
29. Detection rates of nonpalpable prostate cancer in Korean men with prostate-specific antigen levels between 2.5 and 4.0 ng/mL.
Kim HS; Jeon SS; Choi JD; Kim W; Han DH; Jeong BC; Seo SI; Lee KS; Lee SW; Lee HM; Choi HY
Urology; 2010 Oct; 76(4):919-22. PubMed ID: 20303152
[TBL] [Abstract][Full Text] [Related]
30. [The application of high molecular weight cytokeratin in differential diagnosis of prostate adenocarcinoma].
Kong X; Deng F; Wang J
Zhonghua Bing Li Xue Za Zhi; 1996 Aug; 25(4):199-201. PubMed ID: 9275650
[TBL] [Abstract][Full Text] [Related]
31. Benign mimics of prostatic adenocarcinoma on needle biopsy.
Gaudin PB; Reuter VE
Anat Pathol; 1997; 2():111-34. PubMed ID: 9575372
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate.
Herawi M; Epstein JI
Am J Surg Pathol; 2007 Jun; 31(6):889-94. PubMed ID: 17527076
[TBL] [Abstract][Full Text] [Related]
33. Correlation between immunohistochemical patterns and serum levels of PSA and PSAP in prostatic pathology: evaluation of 198 prostatic fine needle biopsies.
Vitali A; Ardoino S; Durante P; Ferro MA; Li Causi F; Parodi C; Sanguineti G; Gaffuri M; Paerachino M; Salvadori RP
Anticancer Res; 1994; 14(4A):1503-7. PubMed ID: 7526771
[TBL] [Abstract][Full Text] [Related]
34. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?
Makarov DV; Sanderson H; Partin AW; Epstein JI
J Urol; 2002 Jun; 167(6):2440-2. PubMed ID: 11992053
[TBL] [Abstract][Full Text] [Related]
35. [Clinical utility of available diagnostic tests in prostatic carcinoma. Results of 500 biopsies. I. PSA, PSA density, and predicted PSA].
Rodríguez Rodríguez R; Mayayo Dehesa T; Galbis Sanjuan F; Jiménez Cidre M; Burgos Revilla FJ; Allona Almagro A; Gomez dos Santos V
Arch Esp Urol; 1997 May; 50(4):333-8. PubMed ID: 9313041
[TBL] [Abstract][Full Text] [Related]
36. High-grade foamy gland prostatic adenocarcinoma on biopsy or transurethral resection: a morphologic study of 55 cases.
Zhao J; Epstein JI
Am J Surg Pathol; 2009 Apr; 33(4):583-90. PubMed ID: 19033862
[TBL] [Abstract][Full Text] [Related]
37. Immediate radical prostatectomy in patients with atypical small acinar proliferation. Over treatment?
Brausi M; Castagnetti G; Dotti A; De Luca G; Olmi R; Cesinaro AM
J Urol; 2004 Sep; 172(3):906-8; discussion 908-9. PubMed ID: 15310995
[TBL] [Abstract][Full Text] [Related]
38. A clinical and immunohistochemical study of papillary adenocarcinoma of the prostate.
Ito T; Furusato M; Akiyama A; Kato H; Aizawa S
Prostate; 1995 Jan; 26(1):23-7. PubMed ID: 7531325
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical expression of Ets-related gene-transcriptional factor in adenocarcinoma prostate and its correlation with Gleason score.
Mannan R; Bhasin TS; Manjari M; Singh G; Bhatia PK; Sharma S
Indian J Pathol Microbiol; 2016; 59(4):489-495. PubMed ID: 27721279
[TBL] [Abstract][Full Text] [Related]
40. Validation of cytokeratin 5/6 as an effective substitute for keratin 903 in the differentiation of benign from malignant glands in prostate needle biopsies.
Abrahams NA; Ormsby AH; Brainard J
Histopathology; 2002 Jul; 41(1):35-41. PubMed ID: 12121235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]